

BioSign® Mono

For Whole Blood, Serum or Plasma

Rapid Heterophile Antibody Test for
Infectious Mononucleosis

For *in vitro* Diagnostic Use

Immunoassay for the Qualitative Detection of
Infectious Mononucleosis Heterophile Antibodies
in Whole Blood, Serum or Plasma

	Serum/Plasma	Whole-Blood
CLIA Complexity:	Moderate	Waived
CDC Analyte Identifier Code:	2809	2809
CDC Test System Identifier Code:	37122	37143

Catalog No.	BSP-402WB-35	35 Test Kit
	BSP-402WB-10	10 Test Kit

Intended Use

BioSign® Mono test qualitatively detects infectious mononucleosis antibodies in human whole blood, serum or plasma specimens. This test is intended for use as an aid in the diagnosis of infectious mononucleosis.

Summary and Explanation

Infectious mononucleosis (IM) is an acute, self-limited, lymphoproliferative disease caused by the Epstein-Barr virus (EBV). Infection with EBV usually occurs early in life with no recognizable disease. When primary infection is delayed until young adulthood and adolescence, however, there is about a 50% chance that it will occur with the classic clinical manifestations associated with IM (1,2).

The diagnosis of IM is usually based on the evaluation of characteristic clinical, hematological, and serological changes. In most cases of IM, clinical diagnosis can be made from the characteristic triad of fever, pharyngitis, and cervical lymphadenopathy, lasting for 1 to 4 weeks. IM may be complicated by splenomegaly, hepatitis, pericarditis, or central nervous system involvement(3). Rare fatal primary infections occur in patients with histiocytic hemophagocytic syndrome(4) or with a genetic X-linked lymphoproliferative syndrome(5). Hematologic features of IM include lymphocytosis with prominent atypical lymphocytes. Because other diseases may mimic the clinical and hematological symptoms of IM, serological testing is essential for the most accurate diagnosis. Serological diagnosis of IM is demonstrated by the presence of heterophile and EBV antibodies in the sera of patients (2, 6, 7).

It has been well established that most individuals exposed to EBV develop a heterophile antibody response. Heterophile antibodies make up a broad class of antibodies which are characterized by the ability to react with surface antigens present on erythrocytes of different mammalian species. It is not known which specific antigen stimulates their production. It has been a common practice for physicians to use the detection of IM heterophile antibodies in the blood of patients as an aid in the diagnosis of IM. **BioSign® Mono** assay utilizes an extract of bovine erythrocytes which gives a greater sensitivity and specificity than similar extracts prepared from sheep and horse erythrocytes. The Forssman antibody interference has been known to be minimized by using the bovine erythrocyte extract (8,9).

Principle

BioSign® Mono one-step antibody test for IM uses direct solid-phase immunoassay technology for the qualitative detection of IM heterophile antibodies in human serum, plasma or whole blood. In the test procedure, 10 µl serum or plasma are added in the **Sample Well (S)** located below the result window. For finger-tip or whole blood, 25 µl of blood is added in the **Sample Well (S)**. If any IM-specific heterophile antibody is present in the sample, it will be captured by the antigen band (bovine erythrocyte extracts) impregnated in the test membrane. The developer solution is then added in **Sample Well (S)**. As the specimen followed by the developer moves by capillary action to the antigen band, the solution mobilizes the

dye conjugated to anti-human IgM antibodies. Visualization of the antigen band at the **Test position (T)** in the result window will occur only when the IM-specific heterophile antibody which has been bound to the extracted antigen obtained from bovine erythrocytes. As the antibody-dye conjugate continues to move along the test membrane, it will bind to another band located at the **Control position (C)** to generate a colored band regardless of the presence of IM heterophile antibodies in the sample. Therefore, the presence of two colored bands, one at the **Test position (T)** and the other at the **Control position (C)**, indicates a positive result, while the absence of a colored band at the **Test position (T)** indicates a negative result.

Reagents and Materials Provided

- **BioSign® Mono** test devices containing a membrane strip coated with bovine erythrocyte extract and a pad impregnated with the monoclonal mouse anti-human IgM antibody-dye conjugate in a protein matrix containing 0.1% sodium azide.
- Developer Solution: Phosphate saline buffer containing 0.2% sodium azide as preservative.
- Package insert

Materials required but not provided:

- Centrifuge capable of 1500 x g
- Micropipette (200 µl)

Precautions

- The reagents in this kit contain sodium azide. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with a large amount of water to prevent azide buildup. Decontamination procedures for azide contaminated plumbing are available upon request from PBM Technical Services.
- Human blood and its products are potentially infectious; handle with appropriate precautions.
- For *in vitro* diagnostic use
- Do not interchange reagents from different kit lots or use beyond the expiration date. The reagent in each kit are tested by Quality Control to function as a unit to assure proper sensitivity and maximum accuracy.
- Use **BioSign® Mono** test only in accordance with instructions supplied with the kit.

Storage and Stability

BioSign® Mono test kit should be stored at 2°–30°C (36°–86°F) in its sealed pouch. Do not freeze. The storage conditions and stability dating given were established under these conditions.

Specimen Collection and Preparation

Whole Blood:

a). Anticoagulated Blood:

Whole blood collected over CPDA-1, heparin or EDTA can be used in this test. Mix whole blood by inversion and use in the test as outlined in the Test Procedure. Whole blood can be stored at 2°-8°C for 24 hours. If testing is anticipated after 24 hours, separate plasma, as outlined above, and freeze at or below -20°C.

Caution: Do not freeze & thaw whole blood; hemolyzed blood can not be used in this test.

b). Fingertip Blood:

For fingertip blood, prick the finger and discard the first drop. Wipe the finger and use a micropipette to collect 25 µl of blood from the second drop. Immediately transfer the blood on to the upper end of the **Sample Well (S)** of the test device as outlined in the “Test Procedure”.

Serum or Plasma:

Use serum or plasma obtained from blood collected aseptically by venipuncture into a clean tube. If serum or plasma filter isolates are used, follow the manufacturer’s instructions.

For serum, no anticoagulant should be used. For plasma, collect the whole blood specimen into a tube containing anticoagulant such as CPDA-1, heparin, or EDTA. For serum, blood should be allowed to clot at room temperature (18°-24°C) and then centrifuged at 1500 x g for ten minutes at room temperature. The serum should be separated as soon as possible and may be tested immediately.

Remove the serum or plasma from the clot or red cells as soon as possible to avoid hemolysis. When possible, clear, nonhemolyzed specimens should be used. Mildly hemolyzed specimens do not affect the test result, but may create an undesirable reddish background in the result window. Specimens containing any particulate matter may give inconsistent test results. Such specimens should be clarified by centrifugation prior to testing.

Storage of specimens - Refrigerate all specimens at 2°- 8°C until ready for testing. If serum or plasma specimens will not be tested within 48 hours of collection, they should be stored at or below -20°C. Specimens should not be repeatedly frozen and thawed. If specimens are to be mailed, they should be packed in appropriate shipping containers as currently described by the carrier services for handling of potentially infectious materials.

Procedure

Procedural notes

- The test protocol must be followed in order to achieve optimal test reactivity with specimens. Follow the assay procedure and always perform the test under carefully controlled conditions.
- Allow **BioSign® Mono** test devices, reagents and specimens to warm to room temperature before testing.
- BioSign® Mono** test device should remain in the sealed pouch prior to testing.
- To avoid cross-contamination, use a new micropipette tip for each specimen.
- Label the device with the patient's name or control number.
- When specimen is dispensed using a micropipet, allow the tip of the micropipet to touch lightly to the membrane at the UPPER END of the **Sample Well (S)** and then release the contents by pressing the micropipet lever.
- When the finger-tip blood is dispensed, allow a free flow drop to form. Do not squeeze the finger too hard. Follow instructions under "Specimen Collection and Preparation."
- To add the Developer Solution, hold the dropper bottle in a vertical position above the LOWER END of the **Sample Well (S)** and dispense 2-3 drops in the well.
- Mildly hemolyzed whole blood specimens do not affect the test result, but may create an undesirable reddish background in the result window.
- To avoid contamination, do not touch the tip of the Developer Solution dropper bottle to skin or **BioSign® Mono** test device.
- Use accepted microbiological practices for proper disinfection of potentially infectious test materials and contaminated equipment disposal.
- After testing, dispose of **BioSign® Mono** test devices, micropipette tip and specimens in approved biohazard containers.

Quality Control

There are two internal control features in **BioSign® Mono** test. A colored control band will always appear at the **Control position (C)** if the test has been performed correctly and if the device is working properly. This is considered an internal positive procedural control. A clear background in the result window is considered an internal negative procedural control. If the test has been performed correctly and **BioSign® Mono** device is working properly, the background in the result window will be clear, providing a distinct result.

If the colored control band does not appear at the **Control position (C)**, the test is invalid and a new test should be performed. If the problem persists, contact PBM Technical Services immediately for assistance.

External controls may also be used to assure that the reagents are working properly and the assay procedure is followed correctly. It is recommended that a control be tested at regular intervals as good laboratory testing process. For information on how to obtain controls, contact PBM's Technical Services.

Test Procedure


NOTE: A positive test result may be read as soon as a distinct pink-purple colored band appears at the **Test position (T)** and at the **Control position (C)**. Any shade of pink-purple colored horizontal band at the **Test position (T)** should be reported as a positive result. The intensity of the colored band at the **Test position (T)** may be different than the intensity of the band at the **Control position (C)**.

A. For Serum or Plasma:

Step 1. Using a micropipette, add 10 µl of serum or plasma to the UPPER END of the **Sample Well (S)**.

Step 2. Add 2-3 drops of Developer Solution into the LOWER END of the **Sample Well (S)**.

Step 3. Read test results at 8 minutes. A strong positive result may appear in less than 3 minutes. Waiting 8 minutes is required to report a negative result. Results are stable up to 15 minutes after the addition of the Developer Solution.



B. For Whole Blood:

Step 1. Using a micropipette, add 25 µl of whole blood to the UPPER END of the **Sample Well (S)** of the device.




Step 2. Add 2-3 drops of Developer Solution into the LOWER END of the **Sample Well (S)**.

Step 3. Read test results at 8 minutes. A strong positive result may appear in less than 3 minutes. Waiting 8 minutes is required to report a negative result. Results are stable up to 15 minutes after the addition of the Developer Solution.

Interpretation of Results


Positive:

One pink-purple colored horizontal band each at the **Test position (T)** and at the **Control position (C)** indicate that IM-specific heterophile antibodies have been detected.




Negative:

One pink-purple colored band at the **Control position (C)**, with no distinct colored horizontal band at the **Test position (T)** other than the normal faint background color, indicates the IM-specific heterophile antibodies have not been detected.



Invalid:

A distinct colored horizontal band at the **Control position (C)** should always appear. The test is invalid if no such band forms at the **Control position (C)**.



BioSign® Mono test is optimized to have a minimal prozone effect. Therefore, specimens containing a very high titer of antibody may produce a somewhat weaker signal but would still produce a positive result. The test does not require any specimen dilution, but it is recommended that the specimen be diluted and retested to confirm the result in case a prozone effect is suspected. The test should be used only for the qualitative detection of heterophile antibody.

Limitations of the Procedure

- The results obtained by this kit yield data which must be used only as adjunct to other information available to the physician.
- Although most patients will have a detectable heterophile antibody level within three weeks of infection, occasionally a patient with strong clinical signs of IM may take longer than three months to develop a detectable level (10). If further testing is desired, collect additional specimens every few days and retest.
- Some segments of the population who contract IM do not produce measurable levels of heterophile antibody. Approximately 50% of children under 4 years of age who have IM may test as IM heterophile antibody negative (11). EBV-specific laboratory diagnosis may be helpful in these cases.
- Some individuals are reported to maintain a low but persistent level of heterophile antibodies long after their primary illness. Heterophile antibodies have been detected in blood specimens taken more than one year after the onset of the illness (12). Such false positive test results occurring in 2-3% of patients can be excluded by EBV-specific serology (3).
- The IM heterophile antibody has been associated with disease states other than IM, such as leukemia, cytomegalovirus, Burkitt's lymphoma, rheumatoid arthritis, adenovirus, viral hepatitis, and *Toxoplasma gondii* (13). In primary infections of adults with clinically atypical diseases, EBV-specific laboratory diagnosis may also be helpful.
- **BioSign® Mono** for serum and plasma is classified as moderately complex under the CLIA '88 regulations. **BioSign® Mono** for whole blood test is classified as waived under the CLIA '88 regulations.
- Open or broken/damaged pouches may produce erroneous results due to kit instability from exposure to moisture and should be discarded - Do Not Use.

Expected Values

1. In patients with symptoms indicating IM, a positive heterophile antibody result is diagnostic, and no further testing is necessary. During the acute phase of illness, IM-specific heterophile antibodies are detectable in 80-85% of IM cases. Humoral responses to primary infections appear to be quite rapid. Moderate to high levels of heterophile antibodies are seen during the first month of illness and decrease rapidly after week four (3).
2. Positive test results may persist for months or even years due to the presence of persistent IM heterophile antibodies (14). This may occur with or without any clinical symptoms or hematological evidence of IM (12, 15-17). Conversely, a confirmed heterophile antibody test may indicate an occult infection (18, 19). In fact, detection of IM prior to onset of clinical symptoms has been reported (20, 21).
3. Some patients remain persistently negative, even though there may exist hematological and clinical evidence of IM (13, 22). In some of these patients, serological evidence for a diagnosis of cytomegalovirus infection, toxoplasmosis, or viral hepatitis, as well as others, have been found (13,

Performance Characteristics**Specificity**

The following potentially interfering substances do not interfere with infectious mononucleosis heterophile antibody determinations in **BioSign® Mono** Assay up to the levels shown below:

Human Albumin	15 g/dL
Bilirubin	60 mg/dL
Hemoglobin	1 g/dL
Triglycerides	1,300 mg/dL

Proficiency Testing Results

Venous blood was taken from 20 individuals. Five samples out of twenty were spiked with mononucleosis positive serum. Plasma was separated from these samples to test with **BioSign® Mono** kit. These spiked and unspiked samples were provided to a clinical POL site for blind testing. The results showed 100% correlation.

Clinical Testing Results

A total of 432 whole blood clinical samples (152 finger-stick and 280 venous blood) were tested at 7 different Physician Office Laboratory (POL) clinical sites, a reference laboratory, and in-house. Concurrently, serum or plasma samples from the same patients were obtained and tested at the same sites. In addition, a total of 144 serum/plasma samples were tested at a reference laboratory clinical site (Table 1).

Table 1: Clinical Sample Testing Arrangement

Site	Finger Stick Blood	Venous Whole Blood	Serum /Plasma	Total
POL No. 1	0	50	0	50
POL No. 2	0	50	0	50
POL No. 3	6	42	0	48
POL No. 4	20	13	0	33
POL No. 5	31	31	0	62
POL No. 6	51	0	0	51
POL No. 7	17	17	0	34
Reference Lab	0	50	144	194
In-house	27	27	0	54
Total	152	280	144	576

Venous whole blood samples were tested with **BioSign® Mono**, and the corresponding serum/plasma samples were tested with a commercially available immunochromatographic heterophile antibody assay (Predicate) kit. When a finger stick blood sample was tested with **BioSign® Mono**, venous whole blood was drawn from the same patient at the same time. The plasma or serum was then prepared from each venous whole blood sample and run on a **BioSign® Mono** device. **BioSign® Mono** results were compared with the commercially available immunochromatographic heterophile antibody assay (Predicate) test results (Table 3). In the case of serum/plasma samples, each sample was run on both **BioSign® Mono** and the commercially available immunochromatographic heterophile antibody assay devices, and the results were compared (Table 4). Table 2 combines both results shown in Tables 3 and 4.

Table 2 shows that *the agreement between two tests was 99.0% (570/576)*. **BioSign® Mono** demonstrated a relative specificity of 98.8% (479/485) and a relative sensitivity of >99.9% (91/91). The results obtained with the **BioSign® Mono** test correlated well to the results obtained with the commercially available immunochromatographic heterophile antibody assay test.

Table 2: Total Specimens

		BioSign® Mono		
		Positive	Negative	Total
Commercially available	Positive	91	0	91
immunochromatographic	Negative	6	479	485
heterophile antibody assay	Total	97	479	576

Table 3: Whole Blood (Finger Stick and Venous)

		BioSign® Mono		
		Positive	Negative	Total
Commercially available immunochromatographic heterophile antibody assay	Positive	77	0	77
	Negative	6	349	355
Total		83	349	432

Table 4: Serum or Plasma Specimens

		BioSign® Mono		
		Positive	Negative	Total
Commercially available immunochromatographic heterophile antibody assay	Positive	14	0	14
	Negative	0	130	130
Total		14	130	144

References

- Davidson I. Serologic Testing of Infectious Mononucleosis. J. Am. Med. Assoc. 183:289, 1937
- Evans, A.S. History of Infectious Mononucleosis. Am J Med Sci 267:189, 1974
- Lennette, E.T. Epstein-Barr Virus. Manual of Clinical Microbiology, 5th ed., Balows, A., et al (ed.) American Society for Microbiology, Washington DC, pp. 847-852, 1991.
- Grierson, H. and Purtillo, D.T. Epstein-Barr Virus infections in Males with X-linked Lymphoproliferative Syndrome. Ann Intern Med 106:538, 19887.
- Wilson, E.R., et al. Fetal Epstein-Barr Associated Hemophagocystic Syndrome J Pediatr 98:260, 1981.
- Paul J.R. and Bunnell, W.W. The Presence of Heterophile Antibodies in Infectious Mononucleosis. Am J. Med Sci 183:91, 1932.
- Lennette, E. and Henle, W. Epstein-Barr Virus Infections: Clinical and Serological features. Lab Manager 25:23, 1987.
- Baily, G.H. and Raffel, S. Hemolytic Antibodies for Sheep and Ox Erythrocytes in Infectious Mononucleosis. J. Clin Invest 14:228, 1935.
- Fletcher, M.A. and Woodfolk, B.J. Immunological Studies of Infectious Mononucleosis: Isolation and Characterization of Heterophile Antigens from Hemoglobin-free Stroma. J. Immunol 107:842, 1971.
- Penman, H.G. Seronegative Glandular Fever. J. Clin Path 21:50, 1968.
- Fleisher, G.R. Textbook of Human Virology, Belshe, R.B. (ed) Littleton, Mass., PSG Publishing Co., pp 853-886, 1984.
- Evans, A.S., et al. A prospective Evaluation of Heterophile and Epstein-Barr Virus-Specific IgM Antibody tests in Clinical and Subclinical Infectious Mononucleosis: Specificity and Sensitivity of Tests and Persistence of Antibody. J Infect Dis 132:546, 1975.
- Chin, T.D.Y. Diagnostic Criteria and Differential Diagnosis: Infectious Mononucleosis, 2nd ed. Schlossberg, D. (ed) Springer-Verlag, New York, 1990.
- Henle, W.G., et al. Infectious Mononucleosis and Epstein-Barr Virus Associated Malignancies: Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 5th ed. Lennette, E. H. and Schmidt, N.J. (ed) American Public Health Association, Inc., Washington D.C. 1979.
- Henle, G., et al. Relation of Burkitt's Tumor Associated Herpes-type Virus to Infectious Mononucleosis. Proc Natl Acad Sci U.S.A. 59:94, 1968.
- Askinazi, C., et al. Positive Differential Heterophile Antibody Test. Persistence in a Symptomatic Patient. J Am Med. assoc 236:1492, 1976.
- Horwitz, C.A., et al. The Specificity of Heterophile Antibodies in Patients and Healthy Donors with No or Minimal Signs of Infectious Mononucleosis. Blood 47:91, 1976.

- Hallee, T.J., et al. Infectious Mononucleosis at the United States Military Academy: A Prospective Study of a Single Class Over Four Years. Yale J Biol Med 3:182, 1974.
- Infectious Mononucleosis and Its Relationship to EB Virus Antibody. A Joint Investigation by University Health Physicians and P.H.L.S. Laboratories. Br. Med J 11:643, 1971.
- Bauer, S. and Holf, G. Test Detects Mononucleosis in Incubation Period. Annual Meeting of ASCP and CAP, Chicago, Illinois, October 15-23, 1965.
- Baehner, R.L. and Schuler, S.E. Infectious Mononucleosis in Childhood. Clinical Expressions, Serologic Findings, Complications, Prognosis. Clin Pediatr 6:393, 1967.
- Henle, G. and Henle, W. Epstein-Barr Virus and Infectious Mononucleosis. N Engl J Med 288:263, 1964.
- Cameron, D. and McBean, L.M. A Clinical Study of Infectious Mononucleosis and Toxoplasmosis. Baltimore, The Williams and Wilkins Company, pp. 24-27, 1973.

Symbols Key

	Manufactured by
	CEMark
	Authorized Representative
	In Vitro Diagnostic Medical Device
	Catalog Number
	Consult Instructions for Use
	Batch Code
	“Use By” date in year-month-day format
	Temperature Limitation
	Contains sufficient for <n> tests
	Do not reuse
	Contents
	Test Device
	Developer Solution
	Instructions for Use
	Infectious Mononucleosis Test

BioSign® is a Registered Trademark of Princeton BioMeditech Corporation.

Patent No.: 5,559,041

© 2000 PBM
 Printed in U.S.A.
 Revised Oct 2003
 P-5217-A 1009BL

MT Promedt Consulting GmbH
 Eisenbahnstrasse 2
 D-66386 St. Ingbert
 Germany
 +49-68 94-58 10 20

Manufactured by

Princeton BioMeditech Corporation
 Princeton, NJ 08543-7139 U.S.A.
 1-732-274-1000 www.pbmc.com

